This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Miller, H. B. Articles by Hunt, J. S. Search for Related Content Social Bookmarking                   What's this?

Female Sexual Dysfunction: Review of the Disorder and Evidence for Available Treatment Alternatives

Jacquelyn S. Hunt, PharmD, BCPS

With the introduction and marketing of sildenafil, national attention has focused on sexual dysfunction in men. However, strides are being made to focus more effort on evaluation and treatment of female sexual disorder (FSD) since a 1999 national survey reported prevalence rates as high as 43% in women. Evaluation and assessment of FSD requires a comprehensive history and physical examination. Understanding of FSD requires knowledge and understanding of sexual anatomy, physiology, and pathophysiology. Nonpharmacologic treatment may include sex therapy or relationship counseling. Pharmacologic treatment of FSD has focused mainly on hormonal therapies, including estrogen and testosterone, with the majority of studies being done in postmenopausal and hysterectomized women. However, recent studies indicate a more prudent and careful use of hormonal therapies. Research is also moving toward evaluation of bupropion and sildenafil as options for women who suffer from FSD. Available evidence for treatment alternatives is scant and in some cases inconclusive.

Key Words: Female sexual dysfunction • libido • female sexual arousal disorder

Journal of Pharmacy Practice, Vol. 16, No. 3, 200-208 (2003)
DOI: 10.1177/0897190003016003008


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?